Provocative new studies have shown that tight blood pressure (BP) control (goal systolic BP <120 mmHg) in high-risk patients with diabetes mellitus confers no significant cardiovascular benefit other than stroke reduction, and that BP variability is important for the diagnosis and management of hypertension. The impact of these findings on future hypertension guidelines remains to be assessed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cushman, W. C. et al. for the ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
Cooper-DeHoff, R. M. et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304, 61–68 (2010).
Sleight, P. et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens. 27, 1360–1369 (2009).
Turnbull, F. for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527–1535 (2003).
Law, M. R., Morris, J. K. & Wald, N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
US Department of Health and Human Services. National Heart, Lung, and Blood Institute, NIH News. NIH blood pressure trial expands to include more older adults [online], http://www.nih.gov/news/health/oct2010/nhlbi-04.htm (2010).
Rothwell, P. M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 375, 938–948 (2010).
Rothwell, P. M. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375, 895–905 (2010).
Webb, A. J., Fischer, U., Mehta, Z. & Rothwell, P. M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375, 906–915 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S. Oparil has received grants/research support from Daiichi Sankyo Inc., Gilead, and Takeda; she has acted as a consultant for Boehringer-Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Forest Laboratories, NicOx, Novartis, Schering-Plough, The Salt Institute, and VIVUS; and has received Speakers' Bureaue honoraria from Daiichi Sankyo Inc., Merck and Co., and Novartis.
Rights and permissions
About this article
Cite this article
Oparil, S. New challenges in blood pressure goals and assessment. Nat Rev Cardiol 8, 73–75 (2011). https://doi.org/10.1038/nrcardio.2010.201
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2010.201
This article is cited by
-
Twenty-Four-Hour Ambulatory Blood Pressure Reduction with a Perindopril/Amlodipine Fixed-Dose Combination
Clinical Drug Investigation (2013)
-
Management of hypertension in women
Hypertension Research (2012)
